PDCD1 and Hyponatremia: The results revealed that from Q1–2004 to Q2 2024, a narrow-scope search of “Hyponatremia (SMQ)” in the FAERS database identified 1,339 AE reports listing PD-1/PD-L1 inhibitors as the primary suspected drugs, involving 1,274 patients.